Tykerb (lapatinib) — United Healthcare
Breast Cancer
Initial criteria
- One of the following:
- (1) All of the following:
- Diagnosis of recurrent unresectable (local or regional) or stage IV breast cancer
- AND Disease is hormone receptor positive and human epidermal growth factor receptor 2-positive (HER2+)
- AND Used in combination with an aromatase inhibitor [e.g., Aromasin (exemestane), Femara (letrozole), Arimidex (anastrozole)]
- OR
- (2) All of the following:
- Diagnosis of recurrent unresectable or stage IV breast cancer OR breast cancer unresponsive to preoperative systemic therapy
- AND Disease is HER2+
- AND Used as fourth line therapy and beyond in combination with Herceptin (trastuzumab) OR Xeloda (capecitabine)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tykerb therapy
Approval duration
12 months